{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:07:07Z","timestamp":1793138827522,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00415-025-13066-4","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:59:04Z","timestamp":1744455544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-6079","authenticated-orcid":false,"given":"Victoria","family":"Leavitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacynthe","family":"Comtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Brieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus W.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"13066_CR1","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1007\/S10072-021-05165-7","volume":"42","author":"V Meca-Lallana","year":"2021","unstructured":"Meca-Lallana V, Gasc\u00f3n-Gim\u00e9nez F, Ginestal-L\u00f3pez RC et al (2021) Cognitive impairment in multiple sclerosis: diagnosis and monitoring. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 42:5183\u20135193. https:\/\/doi.org\/10.1007\/S10072-021-05165-7","journal-title":"Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"key":"13066_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041249","author":"I Gil-Gonz\u00e1lez","year":"2020","unstructured":"Gil-Gonz\u00e1lez I, Mart\u00edn-Rodr\u00edguez A, Conrad R, P\u00e9rez-San-Gregorio M\u00c1 (2020) Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2020-041249","journal-title":"BMJ Open"},{"key":"13066_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2021.103257","author":"M Gaughan","year":"2021","unstructured":"Gaughan M, Monaghan R, O\u2019Connell K et al (2021) Five-year follow up of the original Irish BICAMS validation cohort. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/J.MSARD.2021.103257","journal-title":"Mult Scler Relat Disord"},{"key":"13066_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/S10072-024-07347-5","author":"A Ny\u00e1ri","year":"2024","unstructured":"Ny\u00e1ri A, Kokas Z, Szamosi S et al (2024) The 7-year follow-up of the Hungarian BICAMS validation cohort implies that cognitive performance may improve in multiple sclerosis patients. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol. https:\/\/doi.org\/10.1007\/S10072-024-07347-5","journal-title":"Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"key":"13066_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2020.102577","author":"E Skorve","year":"2020","unstructured":"Skorve E, Lundervold AJ, Torkildsen \u00d8, Myhr KM (2020) A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/J.MSARD.2020.102577","journal-title":"Mult Scler Relat Disord"},{"key":"13066_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207301.10.1212\/WNL.0000000000207301","author":"N Castrogiovanni","year":"2023","unstructured":"Castrogiovanni N, Mostert J, Repovic P et al (2023) Longitudinal changes in cognitive test scores in patients with relapsing remitting multiple sclerosis: an analysis of the DECIDE Dataset. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207301.10.1212\/WNL.0000000000207301","journal-title":"Neurology"},{"key":"13066_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/ene.14732","volume":"28","author":"MW Koch","year":"2021","unstructured":"Koch MW, Mostert J, Repovic P et al (2021) Is the Symbol digit modalities test a useful outcome in secondary progressive multiple sclerosis? Eur J Neurol 28:2115\u20132120. https:\/\/doi.org\/10.1111\/ene.14732","journal-title":"Eur J Neurol"},{"key":"13066_CR8","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1177\/1352458520987539","volume":"27","author":"MW Koch","year":"2021","unstructured":"Koch MW, Mostert JP, Uitdehaag B, Cutter G (2021) A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Mult Scler 27:1864\u20131874. https:\/\/doi.org\/10.1177\/1352458520987539","journal-title":"Mult Scler"},{"key":"13066_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho PR, Campbell N et al (2018) Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 17:405\u2013415. https:\/\/doi.org\/10.1016\/S1474-4422(18)30069-3","journal-title":"Lancet Neurol"},{"key":"13066_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","volume":"64","author":"RHSR Roxburgh","year":"2005","unstructured":"Roxburgh RHSR, Seaman SR, Masterman T et al (2005) Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 64:1144\u20131151. https:\/\/doi.org\/10.1212\/01.WNL.0000156155.19270.F8","journal-title":"Neurology"},{"key":"13066_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"13066_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","volume":"23","author":"RW Motl","year":"2017","unstructured":"Motl RW, Cohen JA, Benedict R et al (2017) Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler 23:704\u2013710. https:\/\/doi.org\/10.1177\/1352458517690823","journal-title":"Mult Scler"},{"key":"13066_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","volume":"23","author":"P Feys","year":"2017","unstructured":"Feys P, Lamers I, Francis G et al (2017) The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 23:711\u2013720. https:\/\/doi.org\/10.1177\/1352458517690824","journal-title":"Mult Scler"},{"key":"13066_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/1352458518803785","volume":"24","author":"R Kalb","year":"2018","unstructured":"Kalb R, Beier M, Benedict RH et al (2018) Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Sclerosis (Houndmills, Basingstoke, England) 24:1665\u20131680. https:\/\/doi.org\/10.1177\/1352458518803785","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"13066_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2466\/PMS.1977.44.2.367","volume":"44","author":"DMA Gronwall","year":"1977","unstructured":"Gronwall DMA (1977) Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 44:367\u2013373. https:\/\/doi.org\/10.2466\/PMS.1977.44.2.367","journal-title":"Percept Mot Skills"},{"key":"13066_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458509354552","volume":"16","author":"A Drake","year":"2010","unstructured":"Drake A, Weinstock-Guttman B, Morrow S et al (2010) Psychometrics and normative data for the multiple sclerosis functional composite: replacing the PASAT with the symbol digit modalities test. Mult Scler J 16:228\u2013237. https:\/\/doi.org\/10.1177\/1352458509354552","journal-title":"Mult Scler J"},{"key":"13066_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0022-5371(73)80034-9","volume":"12","author":"H Buschke","year":"1973","unstructured":"Buschke H, Bushke H (1973) Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12:543\u2013550. https:\/\/doi.org\/10.1016\/S0022-5371(73)80034-9","journal-title":"J Verbal Learn Verbal Behav"},{"key":"13066_CR18","volume-title":"Brief visuospatial memory test-revised: professional manual","author":"RHB Benedict","year":"1997","unstructured":"Benedict RHB (1997) Brief visuospatial memory test-revised: professional manual. Psychological Assessment Resources Inc, Lutz, FL"},{"key":"13066_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1191\/1352458503MS861OA","volume":"9","author":"RHB Benedict","year":"2003","unstructured":"Benedict RHB, Munschauer F, Linn R et al (2003) Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler (Houndmills, Basingstoke, England) 9:95\u2013101. https:\/\/doi.org\/10.1191\/1352458503MS861OA","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"key":"13066_CR20","volume-title":"BDI-II fast screen for medical patients manual","author":"AT Beck","year":"2000","unstructured":"Beck AT, Steer RA, Brown GK (2000) BDI-II fast screen for medical patients manual. The Psychological Corporation, London"},{"key":"13066_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479\u2013489","journal-title":"Neuroimage"},{"key":"13066_CR22","volume-title":"R: a language and environment for statistical computing","author":"R Core Team **","year":"2021","unstructured":"R Core Team ** (2021) R: a language and environment for statistical computing. Austria, Vienna"},{"key":"13066_CR23","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1212\/WNL.0000000000011123","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch MW, Mostert J, Repovic P et al (2021) Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis. Neurology 96:E111\u2013E120. https:\/\/doi.org\/10.1212\/WNL.0000000000011123","journal-title":"Neurology"},{"key":"13066_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1177\/1352458519876701","volume":"26","author":"MW Koch","year":"2020","unstructured":"Koch MW, Mostert J, Uitdehaag B, Cutter G (2020) Clinical outcome measures in SPMS trials: an analysis of the IMPACT and ASCEND original trial data sets. Mult Scler (Houndmills, Basingstoke, England) 26:1540\u20131549. https:\/\/doi.org\/10.1177\/1352458519876701","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"key":"13066_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/00031305.1976.10479178","volume":"30","author":"G Cutter","year":"1976","unstructured":"Cutter G (1976) Some examples for teaching regression toward the mean from a sampling viewpoint. Am Stat 30:194\u2013197","journal-title":"Am Stat"},{"key":"13066_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2022.104375","author":"TA Fuchs","year":"2022","unstructured":"Fuchs TA, Gillies J, Jaworski MG et al (2022) Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/J.MSARD.2022.104375","journal-title":"Mult Scler Relat Disord"},{"key":"13066_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241249084","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Grossi P, Bellomi F et al (2024) Meaningful cognitive change for the minimal assessment of cognitive function in multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/13524585241249084","journal-title":"Mult Scler"},{"key":"13066_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMOA1803583","volume":"379","author":"RJ Fox","year":"2018","unstructured":"Fox RJ, Coffey CS, Conwit R et al (2018) Phase 2 trial of Ibudilast in progressive multiple sclerosis. N Engl J Med 379:846\u2013855. https:\/\/doi.org\/10.1056\/NEJMOA1803583","journal-title":"N Engl J Med"},{"key":"13066_CR29","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway J, Schuerer N, Alsanousi A et al (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet (London, England) 383:2213\u20132221. https:\/\/doi.org\/10.1016\/S0140-6736(13)62242-4","journal-title":"Lancet (London, England)"},{"key":"13066_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1529100620920576","volume":"21","author":"M L\u00f6vd\u00e9n","year":"2020","unstructured":"L\u00f6vd\u00e9n M, Fratiglioni L, Glymour MM et al (2020) Education and cognitive functioning across the life span. Psychol Sci Public Interest J Am Psychol Soc 21:6\u201341. https:\/\/doi.org\/10.1177\/1529100620920576","journal-title":"Psychol Sci Public Interest J Am Psychol Soc"},{"key":"13066_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004977","author":"JF Sumowski","year":"2018","unstructured":"Sumowski JF, Benedict RHB, Enzinger C et al (2018) Cognition in Multiple Sclerosis: state of the field and priorities for the future. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000004977","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13066-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:42:16Z","timestamp":1747658536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13066-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13066"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13066-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Leavitt received honoraria as consultant on advisory boards, and as a reviewer for the National Institutes of Health and the United States Department of Defense. Dr. Mostert reports no disclosures.\u00a0Dr. Comtois reports no disclosures.\u00a0Dr. Moral received honoraria as consultant in advisory boards, and or as chairperson or lecturer in meetings, or travel support from Actelion, Almirall, Bayer, Biogen-Idec, Bristol Myers Squibb, Merck-Serono, Teva, Novartis Roche and Sanofi-Genzyme.\u00a0Dr. Brieva received honoraria from serving as a speaker and \/ or as a consultant in advisory boards from Bayer, Teva, Celgene, Biogen, Sanofi, Merck-Serono, Novartis, Roche, Allmiral, Bristol Myers Squibb, and Janssen.\u00a0Dr. Repovic received consulting and\/or speaking honoraria from Alexion, Biogen, Celgene, Roche, Sanofi Genzyme, Viela, and EMD Serono.\u00a0Dr. Bowen received honoraria from serving on the scientific advisory board and speaker\u2019s bureau of Biogen, Celgene, EMD Serono, Genentech and Novartis. He has received research support from AbbVie Inc, Alexion, Alkermes, Biogen, Celgene, Sanofi Genzyme, Genentech, Novartis, and TG Therapeutics.\u00a0Dr. Strijbis reports no disclosures.\u00a0Prof. Cutter served on Data and Safety Monitoring Boards: Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb\/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Mapi Pharmaceuticals LTD, Merck, Merck\/Pfizer, Opko Biologics, OncoImmune, Neurim, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, VielaBio Inc, Vivus, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). Consulting or Advisory Boards: Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune, Medday, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion\/Cerexis Pharmaceuticals, Roche, TG Therapeutics. Dr. Cutter is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc. a private consulting company located in Birmingham AL.\u00a0Dr. Koch received consulting fees and travel support from Biogen, Novartis, Roche, Sanofi Genzyme and EMD Serono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"338"}}